secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2022-09-20T23:59:59+00:00
Accession:  0001213900-22-057435
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea Therapeutics appoints Alfred J. Novak to board; two director changes
-----------------------------------------------------------------------------

- Dr. Yassine Bendiabdallah resigned from board on Sept 14, 2022, with no disagreement.
- Dr. Lawrence Steinman resigned from audit committee, remaining on board and as chair of nominating committee.
- Alfred J. Novak appointed to board and audit committee; experienced healthcare executive and former CEO/CFO.
- Mr. Novak previously served on boards of Dova Pharmaceuticals (DOVA), LivaNova (LIVN), and others.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390022057435/0001213900-22-057435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390022057435/ea165864-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-057435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer